Literature DB >> 18413418

Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico.

A M Negrón1, M J Molina, A M Mayor, V E Rodríguez, L M Vilá.   

Abstract

The aim of this study was to determine the factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. A total of 204 patients with systemic lupus erythematosus (per the American College of Rheumatology classification criteria) were evaluated. Metabolic syndrome was assessed using the American Heart Association and the National Heart, Lung, and Blood Institute classification. Socioeconomic-demographic parameters, health-related behaviours, clinical manifestations, autoantibodies, pharmacological treatments, disease activity (per the Systemic Lupus Activity Measure--Revised), and damage accrual (per the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index) were determined at study visit. Factors associated with metabolic syndrome were examined by univariable analyses and multivariable logistic regression models. A total of 196 (96.2%) were women. The mean age at study visit was 43.6 +/- 13.0 years, and the mean disease duration was 8.7 +/- 7.7 years. Seventy-eight patients (38.2%) had metabolic syndrome. In the multivariable analysis, age (odds ratio [OR] = 1.05; 95% confidence interval [CI] 1.02-1.09), government health insurance (OR = 2.06; 95% CI 1.07-4.22), exercise (OR = 0.33; 95% CI 0.14-0.92), thrombocytopenia (OR = 4.19; 95% CI 1.54-11.37), erythrocyte sedimentation rate (OR = 1.64; 95% CI 1.03-2.63), disease activity (OR = 1.14; 95% CI 1.00-1.30), and prednisone >10 mg/day (OR = 3.69; 95% CI 1.22-11.11) were associated with metabolic syndrome. In conclusion, older age, low socioeconomic status, lack of exercise, thrombocytopenia, increased erythrocyte sedimentation rate , higher disease activity, and prednisone >10 mg/day were independently associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico.

Entities:  

Mesh:

Year:  2008        PMID: 18413418      PMCID: PMC2735412          DOI: 10.1177/0961203307086645

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  40 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  The metabolic syndrome: more than the sum of its parts?

Authors:  Muredach P Reilly; Daniel J Rader
Journal:  Circulation       Date:  2003-09-30       Impact factor: 29.690

Review 3.  American College of Endocrinology position statement on the insulin resistance syndrome.

Authors:  Daniel Einhorn; Gerald M Reaven; Rhoda H Cobin; Earl Ford; Om P Ganda; Yehuda Handelsman; Richard Hellman; Paul S Jellinger; David Kendall; Ronald M Krauss; Naomi D Neufeld; Steven M Petak; Helena W Rodbard; John A Seibel; Donald A Smith; Peter W F Wilson
Journal:  Endocr Pract       Date:  2003 May-Jun       Impact factor: 3.443

4.  Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group.

Authors:  G S Alarcón; G McGwin; H M Bastian; J Roseman; J Lisse; B J Fessler; A W Friedman; J D Reveille
Journal:  Arthritis Rheum       Date:  2001-04

5.  Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus.

Authors:  P Rahman; D D Gladman; M B Urowitz; D Hallett; L S Tam
Journal:  Lupus       Date:  2001       Impact factor: 2.911

6.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

7.  The bimodal mortality pattern of systemic lupus erythematosus.

Authors:  M B Urowitz; A A Bookman; B E Koehler; D A Gordon; H A Smythe; M A Ogryzlo
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

8.  The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Yong-Woo Park; Shankuan Zhu; Latha Palaniappan; Stanley Heshka; Mercedes R Carnethon; Steven B Heymsfield
Journal:  Arch Intern Med       Date:  2003-02-24

Review 9.  Predictive value of autoantibodies for activity of systemic lupus erythematosus.

Authors:  J D Reveille
Journal:  Lupus       Date:  2004       Impact factor: 2.911

10.  Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.

Authors:  Elisabet Svenungsson; Iva Gunnarsson; Guo-Zhong Fei; Ingrid E Lundberg; Lars Klareskog; Johan Frostegård
Journal:  Arthritis Rheum       Date:  2003-09
View more
  12 in total

1.  Metabolic syndrome in systemic lupus erythematosus patients : Relationship to disease activity and neuropsychiatric lupus.

Authors:  N Hammam; S M Rashad; A A A Mohamed
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.372

2.  Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants.

Authors:  Alimohammad Fatemi; Azadeh Ghanbarian; Zahra Sayedbonakdar; Mehdi Kazemi; Abbas Smiley
Journal:  Clin Rheumatol       Date:  2018-01-05       Impact factor: 2.980

3.  Prevalence of metabolic syndrome in a cohort of systemic lupus erythematosus patients from Northeastern Brazil: association with disease activity, nephritis, smoking, and age.

Authors:  Marta Maria das Chagas Medeiros; Ídila Mont'Alverne Xavier de Oliveira; Ádilla Thaysa Mendes Ribeiro
Journal:  Rheumatol Int       Date:  2015-07-07       Impact factor: 2.631

4.  Effects of risk factors for and components of metabolic syndrome on the quality of life of patients with systemic lupus erythematosus: a structural equation modeling approach.

Authors:  Jeong-Won Lee; Ji-Hyoun Kang; Kyung-Eun Lee; Dong-Jin Park; Seong Wook Kang; Seung-Ki Kwok; Seong-Kyu Kim; Jung-Yoon Choe; Hyoun-Ah Kim; Yoon-Kyoung Sung; Kichul Shin; Sang-Il Lee; Chang Hoon Lee; Sung Jae Choi; Shin-Seok Lee
Journal:  Qual Life Res       Date:  2017-08-22       Impact factor: 4.147

5.  Metabolic syndrome in Sjögren's syndrome patients: a relevant concern for clinical monitoring.

Authors:  Kristopherson Lustosa Augusto; Eloisa Bonfa; Rosa Maria Rodrigues Pereira; Cleonice Bueno; Elaine Pires Leon; Vilma Santos Trindade Viana; Sandra Gofinet Pasoto
Journal:  Clin Rheumatol       Date:  2015-09-14       Impact factor: 2.980

6.  Metabolic syndrome and associated factors in people with chronic obstructive pulmonary disease.

Authors:  Soo Kyung Park; Janet L Larson
Journal:  West J Nurs Res       Date:  2013-11-29       Impact factor: 1.967

Review 7.  Risk factors in cardiovascular disease in systemic lupus erythematosus.

Authors:  Nailú Angélica Sinicato; Priscila Aparecida da Silva Cardoso; Simone Appenzeller
Journal:  Curr Cardiol Rev       Date:  2013-02-01

8.  Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Julián Caro-Moreno; Nicolás Molano-González; Rubén D Mantilla; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Autoimmune Dis       Date:  2013-11-03

Review 9.  Cardiovascular involvement in autoimmune diseases.

Authors:  Jenny Amaya-Amaya; Laura Montoya-Sánchez; Adriana Rojas-Villarraga
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

10.  Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.

Authors:  Ben Parker; Murray B Urowitz; Dafna D Gladman; Mark Lunt; Rachelle Donn; Sang-Cheol Bae; Jorge Sanchez-Guerrero; Juanita Romero-Diaz; Caroline Gordon; Daniel J Wallace; Ann E Clarke; Sasha Bernatsky; Ellen M Ginzler; David A Isenberg; Anisur Rahman; Joan T Merrill; Graciela S Alarcón; Barri J Fessler; Paul R Fortin; John G Hanly; Michelle Petri; Kristjan Steinsson; Mary Anne Dooley; Susan Manzi; Munther A Khamashta; Rosalind Ramsey-Goldman; Asad A Zoma; Gunnar K Sturfelt; Ola Nived; Cynthia Aranow; Meggan Mackay; Manuel Ramos-Casals; Ronald F van Vollenhoven; Kenneth C Kalunian; Guillermo Ruiz-Irastorza; S Sam Lim; Diane L Kamen; Christine A Peschken; Murat Inanc; Ian N Bruce
Journal:  Ann Rheum Dis       Date:  2014-04-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.